CVS Health Co. (NYSE:CVS) Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC lessened its holdings in CVS Health Co. (NYSE:CVS) by 50.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,263 shares of the pharmacy operator’s stock after selling 27,651 shares during the quarter. Ingalls & Snyder LLC’s holdings in CVS Health were worth $1,610,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wedmont Private Capital grew its stake in shares of CVS Health by 0.8% during the 1st quarter. Wedmont Private Capital now owns 19,225 shares of the pharmacy operator’s stock worth $1,410,000 after purchasing an additional 146 shares during the period. Moody National Bank Trust Division grew its position in CVS Health by 0.7% during the first quarter. Moody National Bank Trust Division now owns 22,268 shares of the pharmacy operator’s stock valued at $1,776,000 after buying an additional 150 shares during the period. Landmark Financial Advisors LLC raised its position in shares of CVS Health by 3.8% in the fourth quarter. Landmark Financial Advisors LLC now owns 4,166 shares of the pharmacy operator’s stock worth $329,000 after acquiring an additional 153 shares during the period. Garland Capital Management Inc. grew its position in shares of CVS Health by 0.3% during the 2nd quarter. Garland Capital Management Inc. now owns 60,810 shares of the pharmacy operator’s stock valued at $3,591,000 after acquiring an additional 160 shares during the period. Finally, Sepio Capital LP increased its stake in shares of CVS Health by 1.7% in the 4th quarter. Sepio Capital LP now owns 9,907 shares of the pharmacy operator’s stock valued at $782,000 after purchasing an additional 163 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Up 0.5 %

CVS stock traded up $0.27 during midday trading on Friday, hitting $57.24. 8,188,057 shares of the company’s stock were exchanged, compared to its average volume of 11,181,803. CVS Health Co. has a 1-year low of $52.77 and a 1-year high of $83.25. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $71.86 billion, a PE ratio of 10.06, a P/E/G ratio of 0.57 and a beta of 0.52. The business has a 50-day simple moving average of $58.50 and a two-hundred day simple moving average of $64.52.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.10. The firm had revenue of $91.23 billion for the quarter, compared to analyst estimates of $91.41 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. CVS Health’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.21 EPS. On average, sell-side analysts predict that CVS Health Co. will post 7 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Monday, July 22nd were issued a $0.665 dividend. The ex-dividend date of this dividend was Monday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.65%. CVS Health’s dividend payout ratio (DPR) is presently 46.75%.

Wall Street Analysts Forecast Growth

Several analysts have commented on CVS shares. Evercore ISI dropped their price objective on CVS Health from $65.00 to $62.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Wells Fargo & Company boosted their price target on shares of CVS Health from $60.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. JPMorgan Chase & Co. decreased their price objective on shares of CVS Health from $101.00 to $86.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Barclays cut their target price on shares of CVS Health from $65.00 to $63.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Robert W. Baird started coverage on CVS Health in a report on Thursday, May 30th. They issued a “neutral” rating and a $61.00 price objective on the stock. Eleven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.24.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.